HMGB1 contributes to the expression of P-Glycoprotein in mouse epileptic brain through toll-like receptor 4 and receptor for advanced glycation end products

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Chen, Yan ^a   Huang, Xian Jing ^a   Yu, Nian ^a   Xie, Yuan ^a   Zhang, Kang ^a   Wen, Fang ^a   Liu, Hao ^b   Di, Qing ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN; SN 50; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; KAINIC ACID; LIPOPOLYSACCHARIDE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CELL ACTIVATION; CELL VIABILITY; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RHODOBACTER SPHAEROIDES; SEIZURE; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; EPILEPSY; METABOLISM;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; EPILEPSY; HMGB1 PROTEIN; KAINIC ACID; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; P-GLYCOPROTEIN; TOLL-LIKE RECEPTOR 4;

EID: 84948961996     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140918     Document Type: Article

References (46)

1. Perucca E, French J, Bialer M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. The Lancet Neurology. 2007; 6(9):793-804. Epub 2007/08/21. doi: 10.1016/s1474-4422(07)70215-6 PMID: 17706563.
2. Aronica E, Gorter JA, Ramkema M, Redeker S, Ozbas-Gerceker F, van Vliet EA, et al. Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia. 2004; 45(5):441-51. doi: 10.1111/j.0013-9580.2004.57703.x PMID: 15101825.
3. Volk H, Potschka H, Loscher W. Immunohistochemical localization of P-glycoprotein in rat brain and detection of its increased expression by seizures are sensitive to fixation and staining variables. The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society. 2005; 53 (4):517-31. Epub 2005/04/05. doi: 10.1369/jhc.4A6451.2005 PMID: 15805426.
4. Lazarowski A, Czornyj L. Potential role of multidrug resistant proteins in refractory epilepsy and antiepi-leptic drugs interactions. Drug metabolism and drug interactions. 2011; 26(1):21-6. doi: 10.1515/DMDI. 2011.006 PMID: 21557674.
5. Hartz AM, Notenboom S, Bauer B. Signaling to P-glycoprotein-A new therapeutic target to treat drug-resistant epilepsy? Drug news & perspectives. 2009; 22(7):393-7. doi: 10.1358/dnp.2009.22.7. 1401354 PMID: 19890496.
6. Potschka H. Modulating P-glycoprotein regulation: future perspectives for pharmacoresistant epilepsies? Epilepsia. 2010; 51(8):1333-47. doi: 10.1111/j.1528-1167.2010.02585.x PMID: 20477844.
7. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annual review of biochemistry. 1993; 62:385-427. Epub 1993/01/01. doi: 10.1146/annurev.bi.62. 070193.002125 PMID: 8102521.
8. Hayashi K, Pu H, Tian J, Andras IE, Lee YW, Hennig B, et al. HIV-Tat protein induces P-glycoprotein expression in brain microvascular endothelial cells. Journal of neurochemistry. 2005; 93(5):1231-41. Epub 2005/06/07. doi: 10.1111/j.1471-4159.2005.03114.x PMID: 15934943.
9. Bauer B, Hartz AM, Pekcec A, Toellner K, Miller DS, Potschka H. Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Molecular pharmacology. 2008; 73(5):1444-53. doi: 10.1124/mol.107.041210 PMID: 18094072.
10. Bauer B, Hartz AM, Miller DS. Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Molecular pharmacology. 2007; 71(3):667-75. doi: 10.1124/mol.106.029512 PMID: 17132686.
11. Yin Y, Li W, Deng M, Zhang P, Shen Q, Wang G, et al. Extracellular high mobility group box chromosomal protein 1 promotes drug resistance by increasing the expression of Pglycoprotein expression in gastric adenocarcinoma cells. Molecular medicine reports. 2014; 9(4):1439-43. doi: 10. 3892/mmr.2014.1961 PMID: 24549588.
12. Walker L, Sills GJ. Inflammation and epilepsy: the foundations for a new therapeutic approach in epilepsy? Epilepsy currents/American Epilepsy Society. 2012; 12(1):8-12. doi: 10.5698/1535-7511-12.1. 8 PMID: 22368518; PubMed Central PMCID: PMC3280476.
13. Maroso M, Balosso S, Ravizza T, Liu J, Bianchi ME, Vezzani A. Interleukin-1 type 1 receptor/Toll-like receptor signalling in epilepsy: the importance of IL-1beta and high-mobility group box 1. Journal of internal medicine. 2011; 270(4):319-26. doi: 10.1111/j.1365-2796.2011.02431.x PMID: 21793950.
14. Vezzani A. Epilepsy and inflammation in the brain: overview and pathophysiology. Epilepsy currents/American Epilepsy Society. 2014; 14(1 Suppl):3-7. doi: 10.5698/1535-7511-14.s2.3 PMID: 24955068; PubMed Central PMCID: PMC3966641.
15. Maroso M, Balosso S, Ravizza T, Liu J, Aronica E, Iyer AM, et al. Toll-like receptor4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nature medicine. 2010; 16(4):413-9. doi: 10.1038/nm.2127 PMID: 20348922.
16. Rizzi M, Caccia S, Guiso G, Richichi C, Gorter JA, Aronica E, et al. Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2002; 22(14):5833-9. Epub 2002/07/18. 20026619. PMID: 12122045.
17. Seegers U, Potschka H, Loscher W. Transient increase of P-glycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainate model of temporal lobe epilepsy. Epilepsy research. 2002; 51(3):257-68. Epub 2002/10/26. PMID: 12399076.
18. Kang R, Chen R, Zhang Q, Hou W, Wu S, Cao L, et al. HMGB1 in health and disease. Molecular aspects of medicine. 2014. doi: 10.1016/j.mam.2014.05.001 PMID: 25010388.
19. Magna M, Pisetsky DS. The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases. Molecular medicine. 2014; 20:138-46. doi: 10.2119/molmed.2013.00164 PMID: 24531836; PubMed Central PMCID: PMC3966993.
20. Chang ZL. Important aspects of Toll-like receptors, ligands and their signaling pathways. Inflammation research: official journal of the European Histamine Research Society [et al]. 2010; 59(10):791-808. Epub 2010/07/02. doi: 10.1007/s00011-010-0208-2 PMID: 20593217.
21. Xie J, Mendez JD, Mendez-Valenzuela V, Aguilar-Hernandez MM. Cellular signalling of the receptor for advanced glycation end products (RAGE). Cellular signalling. 2013; 25(11):2185-97. Epub 2013/07/11. doi: 10.1016/j.cellsig.2013.06.013 PMID: 23838007.
22. Iori V, Maroso M, Rizzi M, Iyer AM, Vertemara R, Carli M, et al. Receptor for Advanced Glycation End-products is upregulated in temporal lobe epilepsy and contributes to experimental seizures. Neurobiology of disease. 2013; 58:102-14. doi: 10.1016/j.nbd.2013.03.006 PMID: 23523633.
23. Baldwin AS Jr. The NF-kappaBand I kappa B proteins: new discoveries and insights. Annual review of immunology. 1996; 14:649-83. doi: 10.1146/annurev.immunol.14.1.649 PMID: 8717528.
24. Yu C, Argyropoulos G, Zhang Y, Kastin AJ, Hsuchou H, Pan W. Neuroinflammation activates Mdr1b efflux transport through NFkappa B: promoter analysis in BBB endothelia. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology. 2008; 22(5-6):745-56. doi: 10.1159/000185558 PMID: 19088456; PubMed Central PMCID: PMC2677694.
25. Yu N, Di Q, Liu H, Hu Y, Jiang Y, Yan YK, et al. Nuclear factor-kappa B activity regulates brain expression of P-glycoprotein in the kainic acid-induced seizure rats. Mediators of inflammation. 2011; 2011:670613. doi: 10.1155/2011/670613 PMID: 21403895; PubMed Central PMCID: PMC3043292.
26. Lubin FD, Ren Y, Xu X, Anderson AE. Nuclear factor-kappa B regulates seizure threshold and gene transcription following convulsant stimulation. Journal of neurochemistry. 2007; 103(4):1381-95. doi: 10.1111/j.1471-4159.2007.04863.x PMID: 17727632.
27. Krikun G, Trezza J, Shaw J, Rahman M, Guller S, Abrahams VM, et al. Lipopolysaccharide appears to activate human endometrial endothelial cells through TLR-4-dependent and TLR-4-independent mechanisms. American journal of reproductive immunology. 2012; 68(3):233-7. Epub 2012/06/08. doi: 10. 1111/j.1600-0897.2012.01164.x PMID: 22672000; PubMed Central PMCID: PMCPmc3418410.
28. Deane R, Singh I, Sagare AP, Bell RD, Ross NT, La Rue B, et al. A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. The Journal of clinical investigation. 2012; 122(4):1377-92. Epub 2012/03/13. doi: 10.1172/jci58642 PMID: 22406537; PubMed Central PMCID: PMCPmc3314449.
29. DAcquisto F, Ianaro A. From willow bark to peptides: the ever widening spectrum of NF-kappaB inhibitors. Current opinion in pharmacology. 2006; 6(4):387-92. Epub 2006/06/20. doi: 10.1016/j.coph.2006. 02.009 PMID: 16781194.
30. Guide for the Care and Use of Laboratory Animals. The National Academies Collection: Reports funded by National Institutes of Health. 8th ed. Washington (DC)2011.
31. Paxinos KBJFa G. The Mouse Brain in Stereotaxic Coordinate London, UK: Elsevier Academic Press; 2007.
32. Balosso S, Maroso M, Sanchez-Alavez M, Ravizza T, Frasca A, Bartfai T, et al. A novel non-transcrip-tional pathway mediates the proconvulsive effects of interleukin-1beta. Brain: a journal of neurology. 2008; 131(Pt 12):3256-65. doi: 10.1093/brain/awn271 PMID: 18952671; PubMed Central PMCID: PMC2724908.
33. Yu N, Liu H, Zhang YF, Su LY, Liu XH, Li LC, et al. Effects of brain IKKbeta gene silencing by small interfering RNAon P-glycoprotein expression and brain damage in the rat kainic acid-induced seizure model. CNS& neurological disorders drug targets. 2014; 13(4):661-72. PMID: 24040792.
34. Williams RL, Risau W, Zerwes HG, Drexler H, Aguzzi A, Wagner EF. Endothelioma cells expressing the polyoma middle T oncogene induce hemangiomas by host cell recruitment. Cell. 1989; 57(6):1053-63. PMID: 2736622.
35. Omidi Y, Campbell L, Barar J, Connell D, Akhtar S, Gumbleton M. Evaluation of the immortalised mouse brain capillary endothelial cell line, b.End3, as an in vitro blood-brain barrier model for drug uptake and transport studies. Brain research. 2003; 990(1-2):95-112. PMID: 14568334.
36. Yoder EJ. Modifications in astrocyte morphology and calcium signaling induced by a brain capillary endothelial cell line. Glia. 2002; 38(2):137-45. PMID: 11948807.
37. Zhou HG, Liu L, Zhang Y, Huang YY, Tao YH, Zhang S, et al. Glutathione prevents free fatty acids-induced oxidative stress and apoptosis in human brain vascular endothelial cells through Akt pathway. CNS neuroscience & therapeutics. 2013; 19(4):252-61. doi: 10.1111/cns.12068 PMID: 23521913.
38. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4):402-8. doi: 10.1006/meth.2001.1262 PMID: 11846609.
39. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-induciblefac-tor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer research. 2002; 62 (12):3387-94. PMID: 12067980.
40. Shen H, Xu W, Luo W, Zhou L, Yong W, Chen F, et al. Upregulation of mdr1 gene is related to activation of the MAPK/ERK signal transduction pathway and YB-1 nuclear translocation in B-cell lymphoma. Experimental hematology. 2011; 39(5):558-69. doi: 10.1016/j.exphem.2011.01.013 PMID: 21300134.
41. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. The Journal of experimental medicine. 2000; 192(4):565-70. PMID: 10952726; PubMed Central PMCID: PMC2193240.
42. Yang J, Huang C, Yang J, Jiang H, Ding J. Statins attenuate high mobility group box-1 protein induced vascular endothelial activation: a key role for TLR4/NF-kappaB signaling pathway. Molecular and cellular biochemistry. 2010; 345(1-2):189-95. doi: 10.1007/s11010-010-0572-9 PMID: 20714791.
43. Volk HA, Burkhardt K, Potschka H, Chen J, Becker A, Loscher W. Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures. Neuroscience. 2004; 123 (3):751-9. PMID: 14706787.
44. Zhang L, Ong WY, Lee T. Induction of P-glycoprotein expression in astrocytes following intracerebro-ventricular kainate injections. Experimental brain research. 1999; 126(4):509-16. Epub 1999/07/28. PMID: 10422714.
45. Heemskerk S, Peters JG, Louisse J, Sagar S, Russel FG, Masereeuw R. Regulation of P-glycoprotein in renal proximal tubule epithelial cells by LPS and TNF-alpha. Journal of biomedicine & biotechnology. 2010; 2010:525180. doi: 10.1155/2010/525180 PMID: 20300455; PubMed Central PMCID: PMC2841251.
46. Holtman L, van Vliet EA, Edelbroek PM, Aronica E, Gorter JA. Cox-2 inhibition can lead to adverse effects in a rat model for temporal lobe epilepsy. Epilepsy research. 2010; 91(1):49-56. doi: 10.1016/j. eplepsyres.2010.06.011 PMID: 20643531.